BMY · Bristol Myers Squibb Co · Documents

Jan 13

Current report 8-K

Regulation FD disclosure

Dec 13

Registration statement S-3ASR

Registration statement

Oct 31

Current report 8-K

Financial results, Regulation FD disclosure

Oct 31

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $11.89B ▲ 8.4% Net income $1.21B ▼ 37.2% Diluted EPS $0.60 ▼ 35.5%

Oct 31

Earnings call

Q3 2024 earnings call

Jul 26

Current report 8-K

Financial results, Regulation FD disclosure

Jul 26

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $12.2B ▲ 8.7% Net income $1.68B ▼ 19.0% Diluted EPS $0.83 ▼ 16.2%

Jul 26

Earnings call

Q2 2024 earnings call

Jun 18

Current report 8-K

Director or officer change, or executive pay

May 9

Current report 8-K Events of May 7

Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Apr 25

Current report 8-K

Financial results, Regulation FD disclosure

Apr 25

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $11.87B ▲ 4.7% Net loss $11.91B Diluted EPS -$5.89

Apr 25

Earnings call

Q1 2024 earnings call

Apr 22

Proxy statement DEFA14A

Proxy statement

Mar 28

Proxy statement DEF 14A Meeting May 7, 2024

Proxy statement

Mar 28

Annual report to holders ARS

Annual report to holders

Mar 28

Proxy statement DEFA14A

Proxy statement

Mar 18

Current report 8-K

Other events

Mar 18

Current report 8-K Events of Mar 13

Director or officer change, or executive pay

Mar 18

Proxy statement PRE 14A Meeting May 7, 2024

Proxy statement

Feb 23

Tender offer SC TO-T/A

Tender offer

Feb 22

Current report 8-K Events of Feb 14

Other events

Feb 16

Tender offer SC TO-T/A

Tender offer

Feb 15

Current report 8-K Events of Feb 13

Director or officer change, or executive pay

Feb 14

Current report 8-K

Other events

Feb 13

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $45.01B ▼ 2.5% Net income $8.03B ▲ 26.8% Diluted EPS $3.86 ▲ 30.8%

Feb 12

Tender offer SC TO-T/A

Tender offer

Feb 2

Current report 8-K

Financial results, Regulation FD disclosure

Feb 2

Earnings call

Q4 2023 earnings call

Jan 25

Tender offer SC TO-T

Tender offer

Jan 8

Current report 8-K

Regulation FD disclosure

Dec 26

Tender offer SC TO-C

Tender offer

Dec 22

Current report 8-K

Other events

Nov 13

Current report 8-K Events of Oct 30

Other events

Oct 31

Current report 8-K/A Events of Apr 21

Director or officer change, or executive pay

Oct 26

Current report 8-K

Financial results, Regulation FD disclosure

Oct 26

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $10.97B ▼ 2.2% Net income $1.93B ▲ 20.0% Diluted EPS $0.93 ▲ 24.0%

Oct 26

Earnings call

Q3 2023 earnings call

Aug 10

Current report 8-K Events of Aug 9

Other events

Jul 27

Earnings call

Q2 2023 earnings call

Jul 27

Current report 8-K

Financial results, Regulation FD disclosure

Jul 27

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $11.23B ▼ 5.6% Net income $2.07B ▲ 45.9% Diluted EPS $0.99 ▲ 50.0%

May 4

Current report 8-K Events of May 2

Director or officer change, or executive pay, Shareholder vote results

Apr 27

Current report 8-K

Financial results, Regulation FD disclosure

Apr 27

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $11.34B ▼ 2.7% Net income $2.26B ▲ 77.0% Diluted EPS $1.07 ▲ 81.4%

Apr 27

Earnings call

Q1 2023 earnings call

Apr 26

Current report 8-K Events of Apr 21

Director or officer change, or executive pay

Apr 26

Proxy statement DEFA14A

Proxy statement

Apr 10

Proxy statement DEFA14A

Proxy statement

Mar 23

Proxy statement DEF 14A

Proxy statement